Abstract

2
Polymorphonuclear neutrophils (PMNs) are the most abundant circulating blood 3 leukocytes. They are part of the innate immune system and provide a first line of defense by 4 migrating toward areas of inflammation in response to chemical signals released from the site. 5
Some solid tumors, such as breast cancer, also cause recruitment and activation of PMNs and 6 release of myeloperoxidase. In this study, we demonstrate that administration of luminol to mice 7 that have been transplanted with 4T1 mammary tumor cells permits the detection of 8 myeloperoxidase activity, and consequently, the location of the tumor. Luminol allowed 9 detection of activated PMNs only two days after cancer cell transplantation, even though tumors 10
were not yet palpable. In conclusion, luminol-bioluminescence imaging (BLI) can provide a 11 pathway towards detection of solid tumors at an early stage in preclinical tumor models. 
Introduction
11
Cancer is a major cause of disease and death in the United States and other countries 12 around the world. For example, the American Cancer Society estimates that 580,350 people will 13 die of cancer in the U.S. in 2013 [1] . Detecting tumors at earlier stages could significantly 14 improve therapeutic outcomes [2, 3] . In pursuing this goal, understanding the tumor 15 microenvironment may facilitate tumor diagnosis at the earliest stages. It has been known that 16 tumor microenvironment differs from that of normal tissue in that it is often characterized by low 17 pH, hypoxia, over-expressed proteases [4] , and infiltration of defensive and immune cells [5] . ) and molecular 26 oxygen (O 2 ) to create an electronically excited oxy-luciferin, which emits visible radiation in the 27 yellow-green to yellow-orange spectrum, with an emission maximum of 560nm [2, 13] Therefore, luminol may be a clinically relevant method for detecting tumors in vivo. To verify the 10 ability of luminol to detect tumors, 4T1 tumors bearing a firefly luciferase gene were generated 11 in Balb/c mice. Luciferin/luciferase is a well-known imaging system that can detect luciferase 12 bearing cells very specifically in vivo. Luciferase detection is clinically irrelevant, though, 13 because clinical tumors do not contain luciferase genes. If luminol imaging could produce 14 images comparable to luciferin in luciferase bearing tumors it would be validated as a tumor 15 detection system. Therefore, luminol bioluminescence was compared to the highly-sensitive but 16
clinically-irrelevant luciferin bioluminescence. We were able to demonstrate using 4T1 tumors 17 in BALB/c mice that MPO detection from neutrophils is especially suited to image tumors very 18 early after implantation. 
Material and Methods
23
Materials and Cell Culture 24
Mouse mammary gland adenocarcinoma tumor cell line 4T1luc2 was purchased from 25
Caliper Life Sciences, Hopkinton, MA. This cell line has been engineered to stably express the 26 firefly luciferase gene luc2 [24] . Cells were grown in RPMI1640 medium supplemented with 10% 27 fetal bovine serum (FBS; Sigma-Aldrich, St. Louis, MO) and 1% penicillin/ streptomycin 28 (Invitrogen, Grand Island, NY). Cells were incubated at 37°C at 95% humidity in 5% CO 2 . 29
Luminol sodium salt was purchased from Gold Biotechnology Inc., St. Louis, MO. Luciferin was 30 purchased from Caliper Life Sciences. 
Bioluminescence imaging 12
As a positive control, the light sensitive substrate D-luciferin (15mg/mL in 1X PBS) was 13
given to the mice intraperitoneally at a dose of 150mg/kg.To demonstrate luminol-dependent 14 bioluminescence, a three hour gap was allowed between D-luciferin and luminol injections. After 15 that, mice were injected intraperitoneally with luminol (30mg/mL in water) at a dose of 300mg/kg. 16
In both cases, mice were placed beneath the CCD camera in an IVIS Lumina II imaging system 17 (Caliper Life Sciences) and retained under isoflurane anesthesia (1.5%-2.0%) for the period of 
Luminol injection kinetics 1
To determine whether the luminol injection route affects luminescence peak signal time 2 at the tumor site, two mice were injected intravenously with luminol (30mg/mL in water) at a 3 dose of 300mg/kg. Two other mice were injected intraperitoneally with luminol (30mg/mL in 4 water) at a dose of 300mg/kg. Both groups were placed beneath the CCD camera of the IVIS 5 system and retained under isoflurane anesthesia (1.5%-2.0%) for the period of imaging (55 6 minutes). Area of 4T1 cells or PBS injection (mammary pad 7) on bioluminescent images was 7 selected as the region of interest (ROI). Boundaries of the ROI were defined based on the 8 luminescence signal on 4T1 cells-injected mice, and the same size area was used in PBS-9 
Luminol imaging 29
Bioluminescence imaging after luminol injection in mice showed a bioluminescence 30 signal at the 4T1luc2 cell injection site (mammary fat pad number seven) on all imaged days 31 starting from Day 1 ( Figure 3A, red lines) . Control mice injected with PBS showed weak signal 32 at the injection site after luminol was administered on Day 1 but no signal on Day 2 ( Figure 3A , 33 blue lines). Apart from the tumor cell injection site, mice showed luminescence at other areas, 1 primarily in the abdominal region. This may be because of peritonitis caused by luminol 2 intraperitoneal injection. Also, some mice showed rectal light ( Figure 3A ) because luminol is 3 known to be removed from the blood and excreted in the faces and this signal is likely due to 4 this natural excretion. There were also small areas of signal in the neck-head region to skin 5 nicking induced by clipping. Bioluminescence signal intensity from the injected area (mammary 6 fat pad number seven) started increasing 2 days after 4T1luc2 cell transplantation, and over 7 time, the signal intensity increased ( Figure 3B) . Also, D-luciferin and luminol bioluminescence 8 intensities showed positive correlations on day 1(R 2 = 0.84), day 2(R 2 = 0.83) and day 3(R 2 = 9 0.82) ( Figure 3C) . 10 11 Figure 3A ,B,C 12 13 14
Luminol injection kinetics 15
To see whether there is any difference in bioluminescence peak signal time at the 16 4T1luc2 cell injection site; mice were imaged after intravenous or intraperitoneal luminol 17 injection. In both cases mice showed peak bioluminescence signal at the tumor area between 18 five and 15 minutes after luminol injection ( Figure 4A saline did show a small signal, the control bioluminescence signal disappeared after two days, 31 in contrast to the transplanted tumor signal. Also, mice showed luminescence at other areas 32 apart from the tumor cell injection site, primarily in the abdominal region. This may be because 33 of peritonitis caused by intraperitoneal luminol injection. Skin nicks due to clipping also 1 produced small signals in the neck and head region on days 1 and 2 after tumor cell inoculation. 2
The intensity of the luminol-based BLI in mammary fat pad 7 increased over time after tumor 3 transplantation. This is the first report of early tumor imaging of solid carcinomas using luminol 4 alone in a preclinical model without additional components. Previously, luminol-based BLI was 5
shown to be effective in early imaging in a transgenic preclinical model of a hematological 6 cancer [17]. Zhang et al. studied the MPO dependence of the luminol bioluminescence signal 7
[21]. When luminol was injected into MPO-positive mice and MPO-deficient mice, no 8 luminescence signal was observed in the group of MPO-deficient mice. Based on these studies 9
[17, 20], it is our paradigm that the luminol BLI signal we detected here is based on MPO activity 10 that been released from activated neutrophils because of tumor transplantation [17] . 11
The emission maximum of luminol-based bioluminescence is at = 425 nm [26] . At this 12 wavelength, tissue penetration (decrease of the luminescence signal to 1/e) is estimated at 0. [39] and gastric carcinoma [40] . Also, it has been reported that neutrophils accumulate in the 5 lungs before the arrival of metastatic cells in breast cancer models [41] . These studies, which 6 demonstrate neutrophil infiltration in different types of tumors, suggest that luminol-based BLI 7 detection of infiltrating neutrophils has potential for early human tumor detection. 8
Luminol has been used in humans for treatment of alopecia areata [42] ; those studies 9 showed it to be safe and rapidly excreted, with no toxic side effects observed. In conclusion, 10 luminol or other luminescent substrates could potentially be used in human patients for imaging 11 tumors. Although this study is a proof-of-principle, the method reported here could potentially be 12 developed to screen for recurrence of other superficial cancers. 13 
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